Biopharmaceutical Cross-Border Technology Transfer Intellectual Property Special Seminar Successfully Held

To support the innovative development of the biopharmaceutical industry, promote international exchange and cooperation and information communication in intellectual property in the field of cross-border technology transfer, help biopharmaceutical enterprises in Jiangsu Province effectively prevent foreign-related legal risks such as intellectual property, data compliance, and regulatory approval in License-in/License-out cross-border technology licensing business, and properly respond to cross-border transaction disputes, the “Biopharmaceutical Cross-Border Technology Transfer Intellectual Property Special Seminar” was successfully held on September 21, 2026. The event was hosted by Jiangsu Rayto, with support from the Legal Committee of the Jiangsu International Chamber of Commerce, the Nanjing Biomedical Industry Intellectual Property Protection Alliance, the Nanjing Intelligent Manufacturing Equipment Industry Intellectual Property Protection Alliance, and PatSnap (Suzhou) Information Technology Co., Ltd.

The event was moderated by Attorney Yujiao Wang, Head of the Patent Department and Partner at Rayto. The following guests were specially invited to give thematic presentations:

Mr. Fengjian Zhang, who has been deeply engaged in pharmaceutical law for nearly twenty years and established and led the legal department of Chia Tai Tianqing in building a legal support system spanning R&D, transactions, commercialization, and corporate governance; Mr. Gustavo de Freitas Morais, Partner and Executive Committee Member of Dannemann Siemsen; Ms. Ling Li, Global Regulatory Expert at Baiming Qicheng Medical Technology (Suzhou) Co., Ltd.; Mr. Zhiwei Wang, Deputy Director of the Protection Division of the Nanjing Intellectual Property Office; and Dr. Jian Wang, Co-founder and Vice President of Suzhou Shengran Weian Intellectual Property Consulting Co., Ltd.

At the same time, leaders and guests from universities and research institutes, biopharmaceutical enterprises, intellectual property service institutions, and other units attended the event on site and participated in the exchange.

In the thematic presentation segment, Mr. Fengjian Zhang, Mr. Gustavo de Freitas Morais, Ms. Ling Li, Deputy Director Zhiwei Wang, and Dr. Jian Wang gave presentations respectively on the following topics: Innovation Without Borders, Data Connecting the World: Going-Global Paths for Biopharmaceutical Enterprises and Cross-Border Data Compliance; Pharmaceutical Intellectual Property and Regulatory Issues in Brazil; High-Risk Medical Devices and Medical Device Combination Products: Analysis of Differences and Strategies in Chinese and International Regulatory Registration, Focusing on EU MDR Challenges and Response Strategies; Brief Introduction to Administrative Adjudication of Patent Infringement Disputes; and IP Due Diligence Issues in Cross-Border Technology Transfer in the Biopharmaceutical Field.

The nearly 3.5-hour sharing session focused on high-value content in the biopharmaceutical field, combining an international perspective with practical depth. It covered multiple hot topics, including going-global paths, data compliance, Brazilian pharmaceutical intellectual property, medical device registration, patent administrative adjudication, and IP due diligence. From the different perspectives of regulatory authorities, international law firms, corporate legal departments, and intellectual property service institutions, the guests provided multi-dimensional professional guidance for biopharmaceutical enterprises in cross-border technology transfer and going-global portfolio planning.

This seminar built a platform for intellectual property exchange, cooperation, and information communication in cross-border technology transfer for biopharmaceutical enterprises in the province, helping enterprises further enhance their capabilities in intellectual property protection, data compliance, regulatory approval, and dispute response in License-in/License-out business. In the future, Rayto will continue to deepen its work in the legal service field of biopharmaceuticals and cross-border technology transfer, join hands with professional forces from all sides, and safeguard the innovative development of the biopharmaceutical industry and enterprises going global.